Latest Thinking in Weight Management

Being overweight or obese increases the risk of a many serious illnesses.

Mysimba® is not indicated for these conditions

Life expectancy is reduced by an average of 3 years in an adult with BMI of 30-35 kg/m² and by 8-10 years in an adult with BMI 40+.1

In a systematic analysis of clinical trials with outcome data observed for at least 2 years, it was found that a 5% reduction in weight has health benefits for those patients “at risk” from their obesity.2

Obesity is a complex, multifactorial disease – a wide range of factors can promote the positive energy balance that leads to obesity. Some of these factors include:3

Homeostatic (hypothalamus) and hedonic (reward system) pathways, are two central nervous system (CNS) pathways that play a key role in the regulation of hunger and reward-driven eating behaviour.4

Obesity adversely affects the health of patients and requires intervention

References:

  1.  NHS Choices. Britain: ‘the fat man of Europe’ 2017. www.nhs.uk/Livewell/loseweight/Pages/statistics-and-causes-of-the-obesity-epidemic-in-the-UK.aspx
    (accessed June 2019).
  2.  Williamson DA, Bray GA and Ryan DH. Obesity 2015;12:2319-2320.
  3.  Sharma AM and Padwal R. Obes Rev. 2010 May;11(5):362-70.
  4.  Billes SK, Sinnayah P, Cowley MA. Pharmacol Res. 2014 Jun;84:1-11.

IE-MYS-139  |  Date of preparation: August 2020

Mysimba®is subject to additional monitoring. To report an adverse event or a product complaint about Mysimba®, please contact: HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517; Website: www.hpra.ie; e-mail: medsafety@hpra.ie Adverse events should also be reported to Adverse events should also be reported to Nalpropion Pharmaceuticals LLC®: 1-800- 902-210 or Mysimba@druginfo.com.

For all other queries, please contact our Irish office at Tel: +353 (0)1 2057760, Fax: +353 (0)1 2698919 or irishoffice@consilienthealth.com

The information on this website is intended for healthcare professionals registered in the Republic of Ireland only.

Mysimba® is a registered trademark of Nalpropion Pharmaceuticals LLC

© 2020 Nalpropion Pharmaceuticals LLC

Other trademarks, registered or otherwise, are the property of their respective owners.